A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results